ScholarIQanswers from OpenAlex & ORCID
Ignacio I. Wistuba
ResearcherPublications, citations & collaboration network
Ignacio I. Wistuba is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Ignacio I. Wistuba have?
ScholarIQindexed works
Ignacio I. Wistuba has 2,825 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ignacio I. Wistuba have?
ScholarIQcitation count
Ignacio I. Wistuba has 106,251 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Ignacio I. Wistuba?
ScholarIQh-index
Ignacio I. Wistuba has an h-index of 156 in OpenAlex.
What is the i10-index of Ignacio I. Wistuba?
ScholarIQi10-index
Ignacio I. Wistuba has an i10-index of 720 in OpenAlex.
What is the ORCID of Ignacio I. Wistuba?
ScholarIQorcid
The ORCID for Ignacio I. Wistuba is on the source record.
What is the OpenAlex record for Ignacio I. Wistuba?
ScholarIQopenalex
The OpenAlex for Ignacio I. Wistuba is on the source record.
What are the most-cited papers on Ignacio I. Wistuba?
ScholarIQmost cited works
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis, Élisabeth Brambilla, Masayuki Noguchi, Andrew G. Nicholson, Kim R. Geisinger, Yasushi Yatabe, David G. Beer, Charles A. Powell, Gregory J. Riely, Paul E. Van Schil, Kavita Garg, John H. M. Austin, Hisao Asamura, Valerie W. Rusch, Fred R. Hirsch, Giorgio V. Scagliotti, Tetsuya Mitsudomi, Rudolf M. Huber, Yuichi Ishikawa, James R. Jett, Montse Sánchez‐Céspedes, Jean‐Paul Sculier, Takashi Takahashi, Masahiro Tsuboi, Johan Vansteenkiste, Ignacio I. Wistuba, Pan‐Chyr Yang, Denise R. Aberle, Christian Brambilla, Douglas B. Flieder, Wilbur A. Franklin, Adi F. Gazdar, Michael K. Gould, P S Hasleton, Douglas W. Henderson, Bruce Johnson, David Johnson, Keith M. Kerr, Keiko Kuriyama, Jin Soo Lee, Vincent A. Miller, Iver Petersen, Victor L. Roggli, Rafael Rosell, Nagahiro Saijo, Erik Thunnissen, Ming‐Sound Tsao, David Yankelewitz
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris, Bruce E. Johnson, Lynne D. Berry, David J. Kwiatkowski, A. John Iafrate, Ignacio I. Wistuba, Marileila Varella‐Garcia, Wilbur A. Franklin, Samuel L. Aronson, Pei-Fang Su, Yu Shyr, D. Ross Camidge, Lecia V. Sequist, Bonnie S. Glisson, Fadlo R. Khuri, Edward B. Garon, William Pao, Charles M. Rudin, Joan H. Schiller, Eric B. Haura, Mark A. Socinski, Keisuke Shirai, Heidi Chen, Giuseppe Giaccone, Marc Ladanyi, Kelly Kugler, John D. Minna, Paul A. Bunn
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt, Matthew D. Hellmann, Mark M. Awad, Justin F. Gainor, Alexa B. Schrock, Ryan J. Hartmaier, Sally E. Trabucco, Laurie M. Gay, Siraj M. Ali, Julia A. Elvin, Gaurav Singal, Jeffrey S. Ross, David Fabrizio, Péter M. Szabó, Chang Han, Ariella Sasson, Sujaya Srinivasan, Stefan Kirov, Joseph D. Szustakowski, Patrik Vitazka, Robin Edwards, José A. Bufill, Neelesh Sharma, Sai‐Hong Ignatius Ou, Nir Peled, David R. Spigel, Hira Rizvi, Elizabeth Jiménez Aguilar, Brett W. Carter, Jeremy Erasmus, Darragh Halpenny, Andrew J. Plodkowski, Niamh M. Long, Mizuki Nishino, Warren L. Denning, Ana Galán‐Cobo, Haïfa Hamdi, Taghreed Hirz, Pan Tong, Jing Wang, Jaime Rodriguez‐Canales, Pamela Villalobos, Edwin R. Parra, Neda Kalhor, Lynette M. Sholl, Jennifer L. Sauter, Achim A. Jungbluth, Mari Mino–Kenudson, Roxana Azimi, Yasir Y. Elamin, Jianjun Zhang, Giulia C. Leonardi, Fei Jiang, Kwok‐Kin Wong, J. Jack Lee, Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba, Vincent A. Miller, Garrett M. Frampton, Jedd D. Wolchok, Alice T. Shaw, Pasi A. Jänne, Philip J. Stephens, Charles M. Rudin, William J. Geese, Lee A. Albacker, John V. Heymach
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah B. Doroshow, Sheena Bhalla, Mary Beth Beasley, Lynette M. Sholl, Keith M. Kerr, Sacha Gnjatic, Ignacio I. Wistuba, David L. Rimm, Ming‐Sound Tsao, Fred R. Hirsch
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack, Brian A. Van Tine, Scott M. Schuetze, James Hu, Sandra P. D’Angelo, Steven Attia, Richard F. Riedel, Dennis A. Priebat, Sujana Movva, Lara E. Davis, Scott H. Okuno, Damon R. Reed, John Crowley, Lisa H. Butterfield, Ruth Salazar, Jaime Rodriguez‐Canales, Alexander J. Lazar, Ignacio I. Wistuba, Laurence H. Baker, Robert G. Maki, Denise K. Reinke, Shreyaskumar Patel